Allozyne

company

About

Allozyne develops technologies that improve the efficacy, safety, dosing, and other characteristics of protein-based therapeutics.

  • 11 - 50

Details

Last Funding Type
Series A
Last Funding Money Raised
$3.50M
Industries
Biotechnology,Health Care,Therapeutics
Founded date
Jan 1, 2005
Number Of Employee
11 - 50
Operating Status
Active

Allozyne develops and commercializes technologies that enable improvements in the efficacy, safety, dosing, and other characteristics of protein-based therapeutics, including peptides, antibodies, and vaccines. Its PEGylated IFN beta is for the treatment of multiple sclerosis. The company was founded in 2005 and is based in Seattle, Washington.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$33.50M
Allozyne has raised a total of $33.50M in funding over 2 rounds. Their latest funding was raised on Oct 26, 2007 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Oct 26, 2007 Series B $30M 1 Detail
Dec 6, 2005 Series A $3.50M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Allozyne is funded by 1 investors. ARCH Venture Partners are the most recent investors.
Investor Name Lead Investor Funding Round
ARCH Venture Partners Series B